Complement activation and inhibition in myocardial ischemia and reperfusion injury
- PMID: 8042849
- DOI: 10.1146/annurev.pa.34.040194.000313
Complement activation and inhibition in myocardial ischemia and reperfusion injury
Abstract
The myocardial inflammatory response that occurs as a result of ischemia and reperfusion is similar to that which occurs in other tissues. Activation of the complement system is an integral part of the initiation and maintenance of any inflammatory response. It and other immune system mediators participate in the promotion of neutrophil adherence to endothelium by modulating expression of various adhesion molecules. The complement system also serves an integral role in mediating neutrophil activation, the results of which have been documented in the setting of myocardial ischemia and reperfusion. Another aspect of the complement cascade, which has received little attention with respect to the heart, is the direct effects of complement activation such as endothelial and myocardial cell cytotoxicity mediated by the membrane attack complex. It is likely that this form of tissue injury contributes significantly to myocardial reperfusion injury. Given the numerous contributions of the complement system to the generation of the inflammatory response, and to directly-mediated tissue injury, selective inhibitors of the complement system have great potential to limit reperfusion injury. This has already been demonstrated for the complement inhibitor sCR1. In the future, it is likely that any therapeutic treatment of reperfusion injury will include modulation of the effects of complement activation.
Similar articles
-
Complement, neutrophils and free radicals: mediators of reperfusion injury.Arzneimittelforschung. 1994 Mar;44(3A):420-32. Arzneimittelforschung. 1994. PMID: 8185717 Review.
-
Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement.Fundam Clin Pharmacol. 2001 Oct;15(5):293-306. doi: 10.1046/j.1472-8206.2001.00040.x. Fundam Clin Pharmacol. 2001. PMID: 11903498 Review.
-
Therapeutic potential of complement inhibitors in myocardial ischaemia.Expert Opin Investig Drugs. 2000 May;9(5):975-91. doi: 10.1517/13543784.9.5.975. Expert Opin Investig Drugs. 2000. PMID: 11060721 Review.
-
Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle.J Immunol. 1993 Jun 1;150(11):5104-13. J Immunol. 1993. PMID: 8496606
-
Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury.Methods Find Exp Clin Pharmacol. 1995 Oct;17(8):499-507. Methods Find Exp Clin Pharmacol. 1995. PMID: 8749222
Cited by
-
Cellular pathophysiology of ischemic acute kidney injury.J Clin Invest. 2011 Nov;121(11):4210-21. doi: 10.1172/JCI45161. Epub 2011 Nov 1. J Clin Invest. 2011. PMID: 22045571 Free PMC article. Review.
-
The heart-bone connection: relationships between myocardial infarction and osteoporotic fracture.Am J Physiol Heart Circ Physiol. 2024 Mar 1;326(3):H845-H856. doi: 10.1152/ajpheart.00576.2023. Epub 2024 Feb 2. Am J Physiol Heart Circ Physiol. 2024. PMID: 38305753 Free PMC article. Review.
-
Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):157-75. doi: 10.1007/s00210-007-0141-2. Epub 2007 Mar 13. Naunyn Schmiedebergs Arch Pharmacol. 2007. PMID: 17394034 Review.
-
The future use of complement inhibitors for the treatment of neurological diseases.Drugs. 1998 Jun;55(6):739-46. doi: 10.2165/00003495-199855060-00001. Drugs. 1998. PMID: 9617589 Review.
-
Linking acute kidney injury to chronic kidney disease: the missing links.J Nephrol. 2017 Aug;30(4):461-475. doi: 10.1007/s40620-016-0359-5. Epub 2016 Dec 7. J Nephrol. 2017. PMID: 27928735 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources